

## **BioLight's New Investment in Sanoculis Ltd., a medical device company which develops an innovative surgical procedure for the ab-interno treatment of the Glaucoma**

Tel Aviv (September 11, 2019) – BioLight is pleased to announce that today, it has signed a binding agreement, together with Mr. Zohar Zisapel, for its investment in Sanoculis Ltd. (the “**Agreement**” and “**Sanoculis**”). According to the Agreement, BioLight shall invest approx. USD 1.1M out of a total investment and loans’ conversions of up to USD 3m (the “**Total Investment**”). Assuming Total Investment, the Company shall hold approx. 5% of the issued and fully paid up share capital of Sanoculis on a fully diluted basis.

To the Company’s best knowledge, the glaucoma surgery market, and in particular the type of surgeries providing a solution for glaucoma from within the eyeball (ab-Interno), including the developing segment of “Minimally Invasive Glaucoma Surgery” (MIGS), to which Sanoculis is aiming at, is a growing global market that requires innovative solutions and improvement of its operations’ effectiveness and safety.

Further, to the Company’s best knowledge, Sanoculis has developed an innovative surgical procedure for the treatment of glaucoma, which can be also used in a combined surgery for the treatment of both glaucoma and cataract (the “**Product**”). Moreover, to the Company’s best knowledge, Sanoculis has a comprehensive clinical data base that supports the efficacy and safety of the Product, and it intends to obtain regulatory approvals for marketing the Product in Europe and the USA.

The investment in Sanoculis is aligned with BioLight's business strategy objectives and plans, and is in-line with its Ophthalmic core activity.